Multiple Myeloma

Final analysis of DREAMM-9 shows promising efficacy data and an optimal dosing schedule for BVRd in transplant-ineligible newly diagnosed multiple myeloma.

RD118 produced an ORR of 94.4% and a median PFS of 18.2 months in heavily pretreated patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD, discusses treatment navigation in relapsed/refractory multiple myeloma in the era of CAR T-cell therapies and bispecific antibodies.

Poll results reflected some of the most anticipated presentations and fields of interest in hematologic oncology at the 2026 ASCO Annual Meeting.

Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.

OncLive announced the 2026 Giants of Cancer Care winners.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.

Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.

Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Elranatamab improved PFS vs SOC combination therapy in relapsed/refractory multiple myeloma, meeting the primary end point of the MagnetisMM-5 trial.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has extended the target action date to review a BLA seeking the approval of subcutaneous isatuximab for multiple myeloma.

China’s NMPA approved belantamab mafodotin plus Vd for the treatment of relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Bortezomib maintenance was associated with lower rates of moderate-to-severe cGVHD in newly diagnosed multiple myeloma after allo-HSCT.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

OPN-6602 received FDA fast track designation for relapsed/refractory multiple myeloma after at least 4 prior lines of therapy.

Zevor-cel produced durable responses in patients with relapsed/refractory multiple myeloma following at least 3 prior lines of therapy.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.